INTRODUCTION
============

Cardiovascular disease (CVD) has been found to be the main cause of all global deaths, resulting in around 30% of deaths per year, while 50% of these deaths are due to CVD directly associated with hypertension.^[@ref1])^ The high prevalence of hypertension and poor blood pressure control are important factors in the rise of CVD burden in the developing countries.^[@ref2])^

Left ventricular hypertrophy (LVH) is the earliest cardiac complication of hypertension and is known to be a major risk factor for cardiac failure, sudden death, stroke, and myocardial infarction.^[@ref3]-[@ref4])^ LV mass is strongly associated with cardiovascular morbidity and mortality.^[@ref5]-[@ref8])^ Studies indicate that there is an increase in the levels of LVH with age, obesity, and blood pressure.^[@ref9]-[@ref12])^

A high rate of proteinuria was seen in the Afghan adult hypertensive population,^[@ref13])^ and the presence of proteinuria has recently been shown to be a cardiovascular risk marker in hypertensive patients.^[@ref14])^ Increased urinary albumin excretion has been considered a marker of renal dysfunction.^[@ref15])^ Similarly, hypertensive patients with microalbuminuria have higher levels of LVH.^[@ref16])^

There is a lack of information on the prevalence of LVH and its relationship with proteinuria in the Afghan adult hypertensive population. Thus, this study was designed to determine the prevalence of LVH and the relationship between LVH and proteinuria among adult hypertensive patients visiting an outpatient clinic in Afghanistan.

MATERIAL AND METHODS
====================

Between December 2014 and August 2016, a total of 789 consecutive hypertensive patients visiting an outpatient clinic in Andkhoy, Afghanistan, were enrolled in the study. The patients were aged ≥18 years and were currently being treated for, were with undiagnosed, or were untreated for hypertension. Hypertension was defined as a systolic blood pressure (SBP)≥140 mmHg or diastolic blood pressure (DBP)≥90 mmHg, with anti-hypertensive medication.^[@ref17])^ Our exclusion criteria included intense physical activity over the last 24 h and pregnancy. Precise enrolled criteria and definition of variables have been already described elsewhere.^[@ref13])^

The results from these measurements were entered into each patient's file. The Sokolow-Lyon index, which is recommended as a diagnostic screening method for LVH, was calculated from the patient's ECG.^[@ref18])^

Statistical Analysis
--------------------

Qualitative variables are shown with their frequency distribution, while quantitative variables are shown as means±standard deviations (SD). Student's *t*-test was used for comparison of the quantitative variables, and chi-squared test was used to compare qualitative variables. A multiple regression model was used to determine the significance of certain predictors of LVH and other variables. *P*-values\<0.05 were considered significant. Data were analyzed using SPSS version 20.0 (SPSS, Chicago, IL). Ethical approval for this study was obtained from the Ethics Committee of Balkh Regional Hospital.

RESULTS
=======

The comparison of baseline sociodemographic and clinical characteristics of all participants is presented in [Table 1](#table1){ref-type="table"}. The mean age of patients with LVH (60.2 \[±11.6\] years) was significantly different from that of patients without LVH (56.4 \[±12.7\] years) (*P*=0.006). The male-to-female ratio among patients with LVH was 2.1, while that in patients without LVH was 0.24. Subjects with MI had significantly higher LVH levels than those without MI (32.4% versus 6.9%, *P*\<0.001). Physical activity had an inverse effect on LVH (71.1% versus 25.0%, *P*\<0.001). The prevalence rate of LVH among patients with proteinuria was greater than the overall prevalence rate of LVH (73.2% versus 54.4%, *P*\<0.001) ([Table 2](#table2){ref-type="table"}) in the study. A significant correlation was observed between proteinuria and LVH (r=0.182, *P*\<0.001).

###### 

Comparison of demographic and clinical characteristics of hypertensive patients with and without LVH

  --------------------------------------------------------------------------------------
                                                 No LVH\       LVH\          *P*-value
                                                 (n=360)       (n=429)       
  ---------------------------------------------- ------------- ------------- -----------
  Age, mean, years, mean±SD                      56.4±12.7     60.2±11.6     0.006

  Female, %                                      289 (80.3%)   137 (31.9%)   \<0.001

  Smokers, %                                     100 (27.8%)   138 (32.2%)   0.332

  Systolic blood pressure, mmHg, mean±SD         152.6±21.5    154.0±27.4    \<0.001

  Diastolic blood pressure, mmHg, mean±SD        93.6±11.9     95.3±14.7     0.001

  Body mass index, kg/m^2^, mean±SD              23.5±4.0      24.0±4.4      \<0.001

  Fasting blood sugar, mean ±SD                  103.5±13.8    105.7±17.1    0.516

  Blood pressure controlled, %                   74 (20.6%)    93 (21.7%)    0.701

  Myocardial infarction, %                       25 (6.9%)     139 (32.4%)   \<0.001

  Diabetes mellitus, %                           47 (13.1%)    75 (17.5%)    0.087

  Total cholesterol≥190 mg/dL, %                 173 (48.1%)   254 (59.2%)   0.002

  Lack of regular physical exercise, %           90 (25.0%)    305 (71.1%)   \<0.001

  Stroke, %                                      14 (3.9%)     22 (5.1%)     0.406

  Heart failure, %                               45 (12.5%)    54 (12.6%)    0.971

  Family history of essential hypertension, %    190 (52.8%)   254 (59.2%)   0.064

  Family history of coronary artery disease, %   76 (21.1%)    131 (30.5%)   0.003

  Family history of diabetes mellitus, %         65 (18.1%)    73 (17.0%)    0.702
  --------------------------------------------------------------------------------------

###### 

Prevalence of LVH among patients with proteinuria

                          LVH           Total         *P*-value     
  ------------- --------- ------------- ------------- ------------- ---------
  Proteinuria   Present   314 (73.2%)   201 (55.8%)   515 (65.3%)   \<0.001
                Absent    115 (26.8%)   159 (44.2%)   274 (34.7%)   \<0.001
                                                                    
  Total                   429 (54.4%)   360 (45.6%)   789 (100%)    

[Table 3](#table3){ref-type="table"} illustrates the results of the multivariate logistic regression analysis determining the relationship between LVH, age, sex, proteinuria, SBP, and DBP. LVH was considered a dependent variable. Patients with a higher level of proteinuria have a high likelihood of having LVH (OR, 1.69; 95% CI, 1.19--2.41). The probability of LVH was estimated to be 1.04 times greater for one-year incremental increase in patient age (95% CI, 1.02--1.05). Women may have a lower risk of having LVH (OR, 0.09; 95% CI, 0.06--0.13). The association between the prevalence of LVH and proteinuria is shown in [Fig. 1](#fig1){ref-type="fig"}

###### 

Multivariate logistic regression analysis for prediction of LVH

  Variables                  OR     95% CI       *P*-value
  -------------------------- ------ ------------ -----------
  Age                        1.04   1.02--1.05   \<0.001
  Female gender              0.09   0.06--0.13   \<0.001
  Proteinuria                1.69   1.19--2.41   0.003
  Systolic blood pressure    1.00   0.99--1.01   0.416
  Diastolic blood pressure   1.00   0.98--1.02   0.891

Abbreviations: OR, odds ratio; CI, confidence interval
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DISCUSSION
==========

As far as the authors are aware, this is the first investigation to evaluate the prevalence of LVH as determined through an ECG and its correlation with proteinuria in the Afghan adult hypertensive population. This correlation confirms that there is a considerable group of adult hypertensive patients at a higher risk for CVD-related death. Furthermore, both proteinuria and LVH levels increase with advanced stages of hypertension. LVH is considered a marker of target organ damage, as well as an independent cardiovascular risk factor that can result in a rise in fibrinogen values and is associated with the development of atherosclerosis.^[@ref19]-[@ref20])^ The prevalence rates of LVH among hypertensive patients in different countries ranged between 20% and 70% according to the study population and criteria used for LVH.^[@ref6]-[@ref8])^ The prevalence rate of LVH at 54.4% among the hypertensive population in the current study falls within these prevalence rates. However, it was higher than that of Japan and the United States, which had reported levels of 15% and 19%, respectively.^[@ref21])^ These differences could arise from the method used to index LV mass and the criteria used for the identification of LVH in the different populations.

We found a positive correlation between proteinuria and LVH. This correlation was demonstrated in other studies.^[@ref22])^ Wachtell *et al.* suggested that angiotensin II is a growth factor that results in LVH as well as renal vascular changes, resulting in an increase in vascular permeability and microalbuminuria.^[@ref16])^

The present study showed that male sex appears to be a stronger risk factor for LVH. This finding concurs with previous studies that reported that men could have a higher likelihood of having LVH than women.^[@ref23])^ However, other studies have shown that female sex was an independent predictor for LVH.^[@ref24]-[@ref26])^ A previous study of Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE) patients with Sokolow-Lyon product LVH indicated a male predominance.^[@ref26])^ Further investigations are needed from this context.

The results of the study show that there is a relationship between LVH and age among hypertensive adult patients. Our finding is consistent with a previous result.^[@ref27])^ However, another study found an inverse relationship between increasing age and the presence of LVH.^[@ref24])^ The determining factors of ECG-LVH among hypertensive subjects were shown to differ based on the methods and criteria used.^[@ref18])^

Some limitations in the study need to be addressed. First, the sample size consisted of only a single-center data source. Therefore, the results of the study would not be generalized. Second, the blood pressure was measured at the outpatient clinic, and there was a lack of data for ambulatory blood pressure assessment during the previous 24 h. Additionally, there was a paucity of laboratory data to assess the correlation between LVH and sCr or eGFR in our study. Finally, there is the lack of information on the duration of blood pressure control as well as a paucity of data about the burden of LVH and the association between LVH and proteinuria in Afghanistan. This is an important examination to evaluate hypertensive patients with proteinuria that will help identify patients at high risk for the treatment. Moreover, the results of our study are in agreement with other studies and should be beneficial in the accumulation of data regarding this issue.

In conclusion, we found a high prevalence rate of LVH and an association between LVH and proteinuria in hypertensive patients in an outpatient clinic in Andkhoy, Afghanistan. Therefore, predicting LVH through the screening of proteinuria using a relatively simple and cheap test at the primary care clinics helps to identify patients at high risk for essential hypertension.
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